王乾一,崔炜,鲁静朝,都军,刘凡,谢瑞芹,杨晓红,谷国强,杨秀春

• 1:河北医科大学第二医院河北省心脑血管病研究所心内科
• 2:河北大学附属医院心内科

摘要(Abstract)：

目的探讨冠心病患者择期PCI及冠状动脉造影术中应用达肝素替代普通肝素的可行性和有效性。方法共入选拟行择期PCI的患者87例,分为普通肝素组(10 000 IU)、小剂量(5 000 IU)达肝素组和大剂量(10 000 IU)达肝素组,分别于用药前及全部剂量的药物注射后10 min、20 min、1 h、2 h及4 h采血,测定活化凝血时间(ACT)及血浆抗凝血因子Ⅹa活性。结果(1)普通肝素组、小剂量达肝素组和大剂量达肝素组ACT均在全部剂量的药物注射后10 min升高至峰值,分别为524.68±278.32 s、191.26±39.35 s、304.20±42.71 s(P<0.05);其后各组ACT开始逐渐回落,在4 h后降至最低。(2)三组抗凝血因子Ⅹa活性均在药物全部注射后20 min达到峰值,分别为0.80±0.11 IU/mL、0.72±0.10 IU/mL及0.72±0.09 IU/mL,但各组间差异无统计学意义(P>0.05)。结论与普通肝素相比,达肝素用于PCI中可达到手术所需抗凝效果。

关键词(KeyWords)： 达肝素;冠状动脉疾病;血管成形术,经腔,经皮冠状动脉;血液凝固因子

Abstract:

Keywords:

基金项目(Foundation): 河北省重大疾病和常见病预防治疗关键技术研究专项(06276107D);; 河北省卫生厅基金资助项目(04043)

作者(Author): 王乾一,崔炜,鲁静朝,都军,刘凡,谢瑞芹,杨晓红,谷国强,杨秀春

参考文献(References)：

• [1]Kereiakes DJ,Kleiman NS,Fry E,et al.Dalteparin in combina-tion with abciximab during percutaneous coronary intervention.Am Heart J,2001,141:348-352.
• [2]Levine GN,Ferrando T.Degree of anticoagulation after one sub-cutaneous and one subsequent intravenous booster dose of enox-aparin:implications for patients with acute coronary syndromesundergoing early percutaneous coronary intervention.J ThrombThrombolysis,2004,17:167-171.
• [3]Martin JL,Fry ETA,Sanderink GJCM,et al.Reliable anticoag-ulation with enoxaparin in patients undergoing percutaneous coro-nary intervention:The pharmacokinetics of enoxaparin in PCI(PEPCI)study.Catheter Cardiovasc Interv,2004,61:163-170.
• [4]Borentain M,Montalescot G,Bouzamondo A,et al.Low-molec-ular-weight heparin vs.unfractionated heparin in percutaneouscoronary intervention:a combined analysis.Catheter CardiovascInterv,2005,65:212-221.
• [5]Madan M,Radhakrishnan S,Reis M,et al.Comparison of enox-aparin versus heparin during elective percutaneous coronary inter-vention performed with either eptifibatide or tirofiban(the actiontrial).Am J Cardiol,2005,95:1295-1301.
• [6]Zalc S,Lemos PA,Esteves A,et al.Early ambulation and vari-ability in anticoagulation during elective coronary stenting with asingle intravenous bolus of low-dose,low-molecular weight hepa-rin enoxaparin.J Invas Cardiaol,2006,18:45-48.
• [7]Natarajan MK,Velianou JL,Turpie AGG,et al.A randomizedpilot study of dalteparin versus unfractionated heparin during per-cutaneous coronary interventions.Am Heart J,2006,151:175.e1-175.e6.
• [8]胡大一,赵秀丽,贾三庆,等.急性冠状动脉综合征介入治疗前应用依诺肝素有效性和安全性研究.中华内科杂志,2003,42:91-93.
• [9]王雷,贾三庆,严松彪,等.抗Xa因子活性测定评价依诺肝素在心导管室中应用的安全性和有效性.中华心血管病杂志,2003,31:111-114.
• [10]朱建华,邱原刚,陈君柱,等.经皮冠状动脉介入治疗中静脉注射那屈肝素的抗血栓疗效及安全性评价.中华心血管病杂志,2005,33:335-339.
• [11]张晓玲,陈方,高阅春,等.低分子肝素在经皮冠状动脉成形术中的应用.中国介入心脏病学杂志,2005,13:23-24.
• [12]陈纪林,陈珏,乔树宾,等.冠心病介入治疗中应用低分子肝素与普通肝素的随机对照研究.中华心血管病杂志,2006,34:127-129.
• [13]朱正炎,胡大一,史旭波,等.激活凝血时间作为达肝素在导管室中应用监测手段的研究.中华内科杂志,2005,44:297-298.
• [14]Hirsh J,Raschke R.Heparin and Low-Molecular-Weight Hepa-rin.Chest,2004,126(Suppl):188S-203S.
• [15]Arjomand H,Surabhi SK,Cohen M.Unfractionated versus frac-tionated heparin for percutaneous coronary intervention.CurrCardiol Rep,2002,4:327-333.
• [16]Levine GN,Ferguson III JJ.Low-molecular-weight heparin dur-ing percutaneous coronary interventions:rationale,results,andrecommendations.Catheter Cardiovasc Interv,2003,60:185-193.
• [17]邱原刚,朱建华,陶谦民,等.经皮冠状动脉介入治疗中静脉注射不同剂量那屈肝素的抗血栓疗效比较.中华心血管病杂志,2004,32:879-883.